LY 367385
目录号 : GC12831An antagonist of mGluR1α
Cas No.:198419-91-9
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
IC50: 8.8 μM
LY 367385 is a selective mGlu1a receptor antagonist for blockade of quisqualate-induced phosphoinositide hydrolysis.
The mGlu family of G-protein-linked glutamate receptors currently comprises eight members by 3,5-dihydroxyphenylglycine can activate specifically Group I mGlu receptors, which have been found to regulate multiple effects in the vertebrate brain.
In vitro: Compared with the activity of LY367385, the novel compound LY367366 antagonizes both mGlu1a and -5 receptors at low micromolar concentrations, but also recruits other subtypes at higher concentrations. LY367366 possessing neuroprotective ability was in general less efficacious than LY357385. This fact suggested that inhibitors of mGlu1 receptors is a potential agent to confer significant neuroprotection [1].
In vivo: LY 367385 and AIDA have been administered intracerebroventricularly (i.c.v.) to lethargic mice and DBAr2 mice, and focally into the inferior colliculus of GEPR. In lethargic mice both compounds significantly decrease the incidence of spontaneous spike and wave discharges on the electroencephalogram, after the administration of LY 367385, 250 nmol, i.c.v. LY 367385, 50 nmol, inhibites spontaneous spike and wave discharges from 30 to 60 min. In DBAr2 mice both compounds produce a rapid, transient suppression of sound-induced clonic seizures. In genetically epilepsy prone rats, both compounds decreases sound-induced clonic seizures. The results suggestes that antagonists of mGlu1 receptors are potential anticonvulsant tools and that activation of mGlu1 receptors likely contributes to a variety of epilepticsyndromes [2].
Clinical trial: So far, no clinical study has been conducted.
References:
[1]. Bruno V, Battaglia G, Kingston A, O'Neill MJ, Catania MV, Di Grezia R, Nicoletti F. Neuroprotective activity of the potent and selective mGlu1a metabotropic glutamate receptor antagonist, (+)-2-methyl-4 carboxyphenylglycine (LY367385): comparison with LY357366, a broader spectrum antagonist with equal affinity for mGlu1a and mGlu5 receptors. Neuropharmacology. 1999 Feb;38(2):199-207.
[2]. Chapman AG, Yip PK, Yap JS, Quinn LP, Tang E, Harris JR, Meldrum BS. Anticonvulsant actions of LY 367385 ((+)-2-methyl-4-carboxyphenylglycine) and AIDA ((RS)-1-aminoindan-1,5-dicarboxylic acid). Eur J Pharmacol. 1999 Feb 26;368(1):17-24.
Cas No. | 198419-91-9 | SDF | |
化学名 | (S)-4-(amino(carboxy)methyl)-3-methylbenzoic acid | ||
Canonical SMILES | OC([C@H](C1=CC=C(C(O)=O)C=C1C)N)=O | ||
分子式 | C10H11NO4 | 分子量 | 209.2 |
溶解度 | <20.92mg/ml in 1.1eq. NaOH | 储存条件 | Desiccate at RT |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 4.7801 mL | 23.9006 mL | 47.8011 mL |
5 mM | 0.956 mL | 4.7801 mL | 9.5602 mL |
10 mM | 0.478 mL | 2.3901 mL | 4.7801 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。